Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

• US 20040058313A1
• Filed: 04/24/2003
• Published: 03/25/2004
• Est. Priority Date: 04/24/2002
• Status: Abandoned Application

• Current Assignee: Marcio Marc Abreu
• Original Assignee: Marcio Marc Abreu
• Inventors: Abreu, Marcio Marc
• Application Number:
  US10/421,956
• Publication Number:
  US 20040058313A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for treating ocular and periocular disorders by administration to a human patient of a therapeutically effective amount of a compound that modulates muscle action.

Claims

1. A method for treating a disorder in a mammal, said method comprising

administering to said mammal an effective amount of a compound that reduces external pressure effects, thereby alleviating external pressure effects experienced by the mammal.

2. The method of claim 1, wherein said compound is gabapentim.

3. The method of claim 1, wherein the compound is a neurotoxin.

4. The method of claim 3, wherein the neurotoxin is botulinum toxin.

5. The method of claim 4, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

6. The method of claim 5, wherein the botulinum toxin is botulinum toxin type A.

7. The method of claim 1, wherein the compound is lidocaine.

8. The method of claim 1, wherein the compound is a combination of lidocaine and alcohol.

9. The method of claim 1, wherein said disorder is at least one of glaucoma, ocular hypertension, diabetic retinopathy, optic neuropathy, retinal vascular occlusion, macular disease, thyroid eye disorder, age-related macular degeneration, macular edema, anterior surface disorder, corneal disorder and retinal disorder.

10. The method of claim 1, wherein the compound is administered by at least one of percutaneously, topically, sub-conjunctivally, by iontophoresis, transdermally using a patch, and as an implant.

11. A method for maximizing the health of the optic nerve and retina in eye disorders by increasing retinal and optic nerve blood flow, said method comprising the steps of

applying to the eye an effective amount of a compound that reduces external pressure effects on the eye in an amount effective to effect such reduction thereby alleviating the pressure inside the eye and increasing blood flow to the eye.

12. The method of claim 11, wherein said compound is gabopentim.

13. The method of claim 11, wherein said eye disorder is at least one of glaucoma, ocular hypertension, diabetic retinopathy, optic neuropathy, retinal vascular occlusion, macular disease, thyroid eye disorder, age-related macular degeneration, macular edema, anterior surface disorder, corneal disorder and retinal disorder.

14. A method for reducing a volume of extraocular muscles, said method comprising the steps of

administering in an enlarged muscle a myotoxic compound in sufficient amounts to reduce the volume of said enlarged muscle.

15. The method of claim 14, wherein said compound is doxorubicin.

16. A method for improving an outcome of refractive surgery, said method comprising the steps of

applying to the eye an effective amount of a compound that reduces external pressure effects on the eye in an amount effective to effect such reduction.

17. A method for improving an outcome of eye surgery for patients with glaucoma, said method comprising the steps of

applying to the eye an effective amount of a compound that reduces external pressure effects on the eye in an amount effective to effect such reduction thereby alleviating an increase of or spike in eye pressure after surgery.

18. The method of claim 17, wherein said eye surgery is at least one of glaucoma, cataract, retina, cornea and plastic.

19. A method for determining an amount of a compound to be administered to a mammal in order to achieve an efficacy needed, the method comprising

a first step of evaluating external pressure effects using lid measuring devices, and

a second step of applying a certain amount of said compound to the mammal based on the results acquired in the first step.

20. The method of claim 19, wherein the method further includes a third step of evaluating external pressure effects using the lid measuring devices after said compound is applied to the mammal.

21. The method of claim 19, wherein the lid measuring devices comprise a contact lens device.

22. A method for treating at least one of glaucoma, ocular hypertension and optic neuropathy in a mammal, said method comprising

administering to said mammal botulinum toxin, thereby alleviating pressure effects.

23. The method of claim 22, wherein the botulinum toxin is administered by at least one of topically, subconjunctivally or intravitreally.

24. A method of protecting against neural damage in a mammal, said method comprising

administering to said mammal an effective amount of a compound that is a neural protective agent, wherein said compound is at least one of botulinum toxin, gabapentin, lidocaine, mexiletine, selegiline and ketamine.

25. The method of claim 24, wherein the compound is administered by at least one of orally, intramuscularly, topically, subconjunctivally or intravitreally.

26. A method of treating a patient for a cosmetic purpose, said method comprising the steps of

administering an effective amount of a combination of lidocaine and alcohol to the patient.

27. The method of claim 26, wherein said cosmetic purpose is the reduction of facial wrinkles.

28. A method of increasing therapeutic efficacy of eye drops to treat glaucoma of a patient, said method comprising

administering to said patient an effective amount of a compound that reduces external pressure effects.

29. The method of claim 28, wherein the eye drop is a prostaglandin analogue.